trader score
-1.59
hit rate
45%
mean α
-0.76%
signals 14d
11
Grade = how their written analysis reads (A best). Trader score = how their last-20 timestamped calls performed vs SPY.
Their picks, scored
Across their last 20 scored bets: 45% hit rate, -0.76% mean alpha, trader score -1.59. Their last-14d mentions, direction-adjusted, have moved +3.0% since posting (mean over 6 mentions with price data).
Recent signals11receipts included
| date (PT) | ticker | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|---|
| 2026-08-24 | · | @ManOnThePen | · | Flags possible state opt-outs from Medicaid coverage of GLP-1 drugs, but details require the link. | · | tweet ↗ |
| 2026-08-21 | LLY | @ManOnThePen | -0.10 | Criticizes Starbucks for ending employee GLP-1 coverage, with mild demand implications for drugmakers | -6.4% | tweet ↗ |
| 2026-08-21 | SBUX | @ManOnThePen | -0.50 | Criticizes Starbucks for ending employee GLP-1 coverage, with mild demand implications for drugmakers | +0.7% | tweet ↗ |
| 2026-08-21 | NVO | @ManOnThePen | -0.10 | Criticizes Starbucks for ending employee GLP-1 coverage, with mild demand implications for drugmakers | -2.4% | tweet ↗ |
| 2026-08-21 | LLY | @ManOnThePen | -0.10 | Highlights the unexpectedly large gray market for retatrutide, relevant to obesity-drug makers | -6.4% | tweet ↗ |
| 2026-08-21 | NVO | @ManOnThePen | -0.10 | Highlights the unexpectedly large gray market for retatrutide, relevant to obesity-drug makers | -2.4% | tweet ↗ |
| 2026-08-19 | · | @ManOnThePen | · | Highlights an exercise-mimicking pill as a potential obesity-treatment development | · | tweet ↗ |
| 2026-08-18 | · | @ManOnThePen | · | Discusses falling GLP-1 prices, manufacturing, trial results, and implications for obesity treatment | · | tweet ↗ |
| 2026-08-18 | · | @ManOnThePen | · | Argues GLP-1 drugs are unlike opioids and that some should become over-the-counter | · | tweet ↗ |
| 2026-08-18 | · | @ManOnThePen | · | Questions whether the claimed GLP-1 mechanism discovery is genuinely groundbreaking | · | tweet ↗ |
| 2026-08-18 | AMLX | @ManOnThePen | -0.30 | Criticizes the expected $150,000 price of Amylyx's Phase 3 GLP-1 antagonist | -1.1% | tweet ↗ |
Grade is our human read-worthiness rating; trader score is a rolling 20-bet hit-rate/alpha composite — different things, often disagreeing. “Since then” is direction-unaware in the table; the summary line above adjusts for which way they leaned.